Orbital Therapeutics
Orbital Therapeutics is dedicated to unleashing the full potential of RNA medicines to treat human diseases in innovative ways. With a comprehensive platform that integrates established and emerging RNA technologies, delivery methods, data science, and automation, the company aims to develop an expansive portfolio of medicines. Their initial focus areas include immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics. Led by a team of scientific pioneers and biopharma industry leaders, Orbital strives to advance the future of RNA medicines and global health.
Industries
Nr. of Employees
small (1-50)
Orbital Therapeutics
Products
Immunomodulatory RNA therapeutics (in vivo CAR and immunomodulator expression)
RNA-based programs designed to modulate the immune system by expressing CARs and other immunomodulatory proteins in vivo for autoimmune disease and oncology indications.
Next-generation mRNA vaccines
Vaccine constructs and regimens that extend beyond first-generation approaches, including heterologous prime–boost strategies, multi-antigen combinations, and polyfunctional designs combining antigen and immune enhancers.
Protein therapeutics delivered via RNA
Programs to deliver therapeutic proteins through RNA platforms, addressing expression durability, protein size and complexity, extrahepatic delivery, and redosing.
Immunomodulatory RNA therapeutics (in vivo CAR and immunomodulator expression)
RNA-based programs designed to modulate the immune system by expressing CARs and other immunomodulatory proteins in vivo for autoimmune disease and oncology indications.
Next-generation mRNA vaccines
Vaccine constructs and regimens that extend beyond first-generation approaches, including heterologous prime–boost strategies, multi-antigen combinations, and polyfunctional designs combining antigen and immune enhancers.
Protein therapeutics delivered via RNA
Programs to deliver therapeutic proteins through RNA platforms, addressing expression durability, protein size and complexity, extrahepatic delivery, and redosing.
Services
Collaborative research agreements and licensing of RNA and non-viral delivery technologies to enable joint development of RNA medicines.
Internal accelerated design–test–optimize workflows combining RNA chemistry, delivery formulation, machine learning, and protein engineering to generate therapeutic candidates.
Collaborative research agreements and licensing of RNA and non-viral delivery technologies to enable joint development of RNA medicines.
Internal accelerated design–test–optimize workflows combining RNA chemistry, delivery formulation, machine learning, and protein engineering to generate therapeutic candidates.
Expertise Areas
- RNA therapeutic design and engineering
- Delivery vehicle engineering (LNPs and VLPs)
- mRNA vaccine development
- Immunomodulatory therapeutics (in vivo expression)
Key Technologies
- Linear mRNA
- Circular RNA
- Lipid nanoparticles (LNPs)
- Virus-like particles (VLPs)
News & Updates
Geno Germano, a veteran in the biopharma industry with extensive development and commercialization experience, has been appointed to Orbital's Board of Directors.
Anna Dixon has been appointed as SVP of Human Resources at Orbital, responsible for HR operations and strategy.
Orbital announced the closing of $270 million Series A financing led by ARCH Venture Partners, supporting the expansion of its RNA platform and portfolio.
Orbital launched with a vision to advance RNA medicines through a state-of-the-art platform and strategic partnerships, aiming to treat a broad range of diseases.
Orbital was a finalist for the 2024 Start-Up of the Year award.
Orbital was a finalist in the 2024 Inno Blazer awards in the Early Stage Biotech category.
Geno Germano, a veteran in the biopharma industry with extensive development and commercialization experience, has been appointed to Orbital's Board of Directors.
Anna Dixon has been appointed as SVP of Human Resources at Orbital, responsible for HR operations and strategy.
Orbital announced the closing of $270 million Series A financing led by ARCH Venture Partners, supporting the expansion of its RNA platform and portfolio.
Orbital launched with a vision to advance RNA medicines through a state-of-the-art platform and strategic partnerships, aiming to treat a broad range of diseases.
Orbital was a finalist for the 2024 Start-Up of the Year award.
Orbital was a finalist in the 2024 Inno Blazer awards in the Early Stage Biotech category.